Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

PloS one - 1 Jan 2013

Baty Florent, Rothschild Sacha, Früh Martin, Betticher Daniel, Dröge Cornelia, Cathomas Richard, Rauch Daniel, Gautschi Oliver, Bubendorf Lukas, Crowe Susanne, Zappa Francesco, Pless Miklos, Brutsche Martin

Abstract excerpt

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identifi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Genes, ras

Share to Quinazolines

Share to ROC Curve

Share to Tumor Burden

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 24039832
DOI: 10.1371/journal.pone.0072966
PMCID: PMC3769372

Genes

EGFR
KRAS
VEGFA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24039832-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.PMID 24039832Read ↗

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.Semantic proximity Read ↗

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Semantic proximity Read ↗

Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.Semantic proximity Read ↗

Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer.Semantic proximity Read ↗

The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profilingSemantic proximity Read ↗

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.